2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
Over the past year, the COVID-19 pandemic has continued to affect the dissemination of critical clinical study findings.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
Combination therapy with cabozantinib and atezolizumab is associated with tolerability and antitumor activity across diverse renal-cell carcinoma histologies.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
The hypoxia-inducible factor-2α inhibitor belzutifan had antitumor activity in treatment-naïve and pretreated disease.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a phase 2 trial, atezolizumab plus bevacizumab showed promise after disease progression on monotherapy with atezolizumab or sunitinib.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a phase 1b/2 study, lenvatinib plus pembrolizumab combination showed promise as first-line therapy and beyond.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
Compared with sorafenib, tivozanib was associated with longer progression-free survival, higher rates of response, and better tolerability in the third-line setting and beyond.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a phase 3 trial, nivolumab combined with cabozantinib improved progression-free survival and overall survival versus sunitinib as first-line therapy.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a phase 3 trial, lenvatinib combined with pembrolizumab improved progression-free survival versus lenvatinib plus pembrolizumab or sunitinib and improved overall survival compared with sunitinib.
2021 Year in Review - Renal-Cell Carcinoma | January 20, 2022
In a phase 3 study, adjuvant pembrolizumab after nephrectomy improved disease-free survival versus placebo in patients with high-risk disease.
- 1
- 2
Page 2 of 2
Results 11 - 19 of 19
Results 11 - 19 of 19
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512